Evidence map›Paper›PMID 41855258›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2026

Elucidation of a potent pro-resolving mediator of inflammation resolution via human neutrophil-vascular endothelial cell interactions.

Robert Nshimiyimana, Nan Chiang, Charles N Serhan

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Robert NshimiyimanaCenter for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115.ORCID 0000-0003-0832-9938
Nan ChiangCenter for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115.ORCID 0000-0003-1963-1585
Charles N SerhanCenter for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115.ORCID 0000-0003-4627-8545

Funding

Evaluating Resolution Mechanisms for Infectious InflammationR35GM139430 · NIGMS · BRIGHAM AND WOMEN'S HOSPITAL · PI SERHAN, CHARLES NICHOLAS · 2021 to 2025
$3.6M
HHS | NIH | National Institute of General Medical Sciences (NIGMS) R35GM139430NIGMS NIH HHS R35 GM139430
6 · The paper itself

Abstract

The acute inflammatory response is a highly coordinated programmed sequence that enables neutrophils to transmigrate from venules into tissues. Ideally self-limited, the active resolution phase produces specialized molecules that stimulate resolution and prevent collateral tissue damage from excessive neutrophil infiltration. The superfamily of pro-resolving molecules is termed specialized pro-resolving mediators including the essential polyunsaturated fatty acid-derived lipoxins, resolvins, protectins, and maresins. Given the intimate interactions between leukocytes and endothelial cells in inflammation resolution, we investigated whether unique bioactive molecules carrying pro-resolution properties are biosynthesized by human neutrophils coincubated with activated vascular endothelial cells. Using metabololipidomics, we found that human coronary aortic valves from transplants contained 13-hydroxy-4Z,7Z,10Z,14E,16Z,19Z-docosahexaenoic acid (13-HDHA) and inflammatory eicosanoids. We report that human endothelial cells convert DHA to 13-HDHA which in turn is transformed by human neutrophils to a previously unknown bioactive product 4,13-dihydroxy-docosahexaenoic acid. This structure was established using physical properties including tandem-mass spectrometry, UV-analysis, and conversion of deuterated substrate. Biosynthesis of this product during neutrophil-endothelial coincubations involved bidirectional crosstalk between neutrophil 5-LOX and endothelial COX-2 as confirmed using isolated recombinant enzymes. The bioactive 4S,13R-dihydroxy-5E,7Z,10Z,14E,16Z,19Z-docosahexaenoic acid, also produced by M2-like macrophages and mononuclear cells, demonstrated potent nanomolar pro-resolving actions including, a) limiting neutrophil infiltration into mouse air pouch, b) reducing human neutrophil adherence to endothelial cells, c) protecting endothelial cell from senescence, and d) stimulating human macrophage efferocytosis of senescent red blood cells. These results provide evidence for a previously unknown pro-resolving pathway and molecule biosynthesized from DHA via cyclooxygenase-2-5-lipoxygenase during leukocyte crosstalk with the vasculature.

Indexed as

Cell CommunicationEndothelial CellsInflammationNeutrophilsAnimalsDocosahexaenoic AcidsHumansLipoxinsSpecialized Pro-Resolving Mediators13,14-dihydroxydocosahexaenoic acidDocosahexaenoic AcidsLipoxinshuman phagocytesleukocytesomega-3 fatty acidsresolvinstranscellular biosynthesis

Identifiers

PMID41855258
PMCPMC13012037

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.